ライフサイエンスコーパス: onchocerciasis

1 ae in blood (lymphatic filariasis) and skin (onchocerciasis).

2 at promise as a simple tool for diagnosis of onchocerciasis.

3 omes many difficulties in identifying active onchocerciasis.

4 Here, we demonstrate NETs formation in human onchocerciasis.

5 rategy in some foci to control and eliminate onchocerciasis.

6 nt regimens against lymphatic filariasis and onchocerciasis.

7 es with a new program that aims to eliminate onchocerciasis.

8 been the drug of choice for the treatment of onchocerciasis.

9 Onchocerca volvulus, the causative agent of onchocerciasis.

10 mosum, which is an important vector of human onchocerciasis.

11 ilariasis, and skin disease and blindness in onchocerciasis.

12 88-2001), only 19.6% of cases were caused by onchocerciasis.

13 sms contribute to the pathogenesis of ocular onchocerciasis.

14 iod; 1283 (5.2%) of these deaths were due to onchocerciasis.

15 red during this period; 29.7% were caused by onchocerciasis.

16 tory reactions after ivermectin treatment of onchocerciasis.

17 to play a role in the development of ocular onchocerciasis.

18 le for antibody in the development of ocular onchocerciasis.

19 Africans who could have been coinfected with onchocerciasis.

20 lein-1 ELISA detected antibodies in 34 of 41 onchocerciasis (83%), 38 of 88 leishmaniasis (43%), 18 o

21 The control of river blindness (onchocerciasis), a human disease transmitted by black fl

22 Human onchocerciasis, a parasitic disease found in 28 African

23 ion, 14 patients treated with ivermectin for onchocerciasis acquired >10 years ago during temporary r

24 Onchocerciasis, also known as "river blindness", is a ne

25 available and emerging diagnostic tests for onchocerciasis and considers how they might be best empl

26 review the development of models concerning onchocerciasis and discuss the various approaches that h

27 ivermectin administration campaigns against onchocerciasis and lymphatic filariasis being conducted

28 drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa.

29 Onchocerciasis and lymphatic filariasis in particular ar

30 Elimination of onchocerciasis and lymphatic filariasis is targeted for

31 matory responses seen following treatment of onchocerciasis and suggest new targets for modulating th

32 n Ov16 with serum samples from patients with onchocerciasis and with various types of control serum s

33 ontribute to the eye defects associated with onchocerciasis and, because there is no counterpart in m

34 a from parasitic (leishmaniasis, Chagas, and onchocerciasis), and infectious diseases (leprosy and So

35 d, and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and the

36 Lymphatic filariasis and onchocerciasis are parasitic helminth diseases that cons

37 Lymphatic filariasis and onchocerciasis are parasitic helminth diseases, which ca

38 Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases

39 dies of the incidence of blindness caused by onchocerciasis are scarce.

40 utility of molecular xenomonitoring (MX) for onchocerciasis as elimination efforts expand into Africa

41 revalence estimation of strongyloidiasis and onchocerciasis as two relevant examples.

42 r filaricidal agents and/or vaccines against onchocerciasis based on immunological and rational hypot

43 s mortality has been noted among people with onchocerciasis, but it is not clear whether this effect

44 he cornerstone of efforts to eliminate human onchocerciasis by 2020 or 2025.

45 d effort could achieve global elimination of onchocerciasis by 2025.

46 the absence of a gold standard, whereas the onchocerciasis case focuses on the identification of vil

47 ssociated adverse reactions in patients with onchocerciasis, changes in plasma tryptase levels and sk

48 Human onchocerciasis - commonly known as river blindness - is

49 doxycycline on a "test and treat" basis for onchocerciasis control and confirm doxycycline as a pote

50 During the past three decades, onchocerciasis control has been successful in reducing b

51 The success of onchocerciasis control has been the result of secure fin

52 t African villages with varying histories of onchocerciasis control measures.

53 rveillance and for evaluating the success of onchocerciasis control measures.

54 Recently, there has been a shift in onchocerciasis control policy, changing from prevention

55 and host mortality with data obtained by the Onchocerciasis Control Programme in West Africa from 231

56 amined, by use of data collected, during the Onchocerciasis Control Programme in western Africa (OCP)

57 parameter values estimated from the Mexican onchocerciasis control programme.

58 implications for a noninvasive host-specific onchocerciasis diagnostic but provides a basis for the m

59 ed drugs, providing starting points for anti-onchocerciasis drug development.

60 orporated into transmission models to inform onchocerciasis elimination efforts in Africa and residua

61 be best employed during different stages of onchocerciasis elimination programs.

62 posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF

63 development of an effective vaccine against onchocerciasis has been the focus of a research program

64 vaccine candidates and drug targets against onchocerciasis has so far been confronted with several l

65 um damnosum s.l., the vector of West African onchocerciasis, has been the target of a major insect co

66 eveloped that include doxycycline to control onchocerciasis in areas where infections persist despite

67 ectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemi

68 als living in an area of hyperendemicity for onchocerciasis in Cameroon were examined.

69 s was determined in a murine model of ocular onchocerciasis in which Ags from the parasitic worm Onch

70 ailable for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helminthiasis, schistosomiasi

71 Human onchocerciasis is a serious neglected tropical disease c

72 velopment of chemotherapeutic agents against onchocerciasis, lymphatic filariasis, and heartworm.

73 patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or other helminthiases an

74 r regulatory submission for the treatment of onchocerciasis, might serve as an alternative to the wid

75 LF (Brugia malayi, Wuchereria bancrofti) or onchocerciasis (Onchocerca volvulus) is doxycycline.

76 ty treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed

77 Onchocerciasis, or river blindness, is a neglected tropi

78 Onchocerciasis, or river blindness, is a neglected tropi

79 h as Onchocerca volvulus, the cause of human onchocerciasis, or river blindness.

80 We assessed the immunoreactivity of onchocerciasis patient sera (n = 152) from the Americas,

81 ive in clearing microfilariae in the skin of onchocerciasis patients with persistent microfilaridermi

82 Attempts to eliminate onchocerciasis, primarily through the mass drug administ

83 be considered a host-specific biomarker for onchocerciasis progression.

84 the rate of blindness from causes other than onchocerciasis remained approximately constant during fo

85 will support future basic and translational onchocerciasis research, with particular relevance for o

86 dentify potential vaccine candidates against onchocerciasis resulted in the cloning of recombinant pr

87 nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blocked worm development an

88 ematodes, including lymphatic filariasis and onchocerciasis (river blindness) has transformed our app

89 gue) and CCR1 using a murine model of ocular onchocerciasis (river blindness) in which neutrophils an

90 Onchocerciasis (river blindness) is a major public healt

91 bundant in the filarial nematodes that cause onchocerciasis (river blindness), including the larvae (

92 us as a natural model or 'analogue' of human onchocerciasis (river blindness), which is caused by Onc

93 ng cause of elephantiasis and hydrocele, and onchocerciasis (river blindness).

94 ion of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helmin

95 , schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that many of them could be cont

96 Since chemotherapy is widely used to treat onchocerciasis, the utility of PCR in assessing response

97 ed methods are needed for field diagnosis of onchocerciasis, to support efforts aimed at elimination

98 In persons with onchocerciasis, topical application of the anthelminthic

99 An onchocerciasis transmission framework (EpiOncho) was cou

100 es-for example, for eye health (trachoma and onchocerciasis), ulcer care (leprosy), or renal support

101 summarizes the progress made to advance the onchocerciasis vaccine from the research laboratory into

102 In comparison, trachoma, onchocerciasis, vitamin A deficiency, and refraction and

103 without a history of control measures where onchocerciasis was endemic, microfilariae (MF) prevalenc

104 Using a mouse model of ocular onchocerciasis, we recently demonstrated that it is thes

105 plains locale-specific infection patterns in onchocerciasis (whereas acquired protective immunity has

106 d to analyse the population biology of human onchocerciasis will be discussed.

107 Treatment of onchocerciasis with diethylcarbamazine (DEC) or ivermect

108 l serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine.

109 Although suppressive therapy for onchocerciasis with intermittent ivermectin prevents the